PATENT CLAIM ANALYSIS

Application Number: 15759815
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "232500"]

Abstract:
The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.

Claim (Index 12):
The method of  claim 11 , wherein the ATM kinase inhibitor is selected from the group consisting of 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide, 2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one and derivatives thereof.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 90.0
- Lexical Diversity: 1.325
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15617543', '10563011', '11245735', '13139058', '13971662']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7704000426478931
- 35 USC 102 Novelty (BERT): 0.5186263965942741
- Combined Prediction Score: 0.7452226780425312
- Mean Citation Score: 250.665504
- Max Citation Score: 275.13943
- Similarity Product: 179.73787719821098

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test